Boron neutron capture therapy of cancer: current status and future prospects.
Reads0
Chats0
TLDR
Critical issues that must be addressed include the need for more selective and effective boron delivery agents, the development of methods to provide semiquantitative estimates of tumor borons content before treatment, improvements in clinical implementation of BNCT, and a need for randomized clinical trials with an unequivocal demonstration of therapeutic efficacy.Abstract:
Background: Boron neutron capture therapy (BNCT) is based on the nuclear reaction that occurs when boron-10 is irradiated with low-energy thermal neutrons to yield high linear energy transfer α particles and recoiling lithium-7 nuclei. Clinical interest in BNCT has focused primarily on the treatment of high-grade gliomas and either cutaneous primaries or cerebral metastases of melanoma, most recently, head and neck and liver cancer. Neutron sources for BNCT currently are limited to nuclear reactors and these are available in the United States, Japan, several European countries, and Argentina. Accelerators also can be used to produce epithermal neutrons and these are being developed in several countries, but none are currently being used for BNCT. Boron Delivery Agents: Two boron drugs have been used clinically, sodium borocaptate (Na 2 B 12 H 11 SH) and a dihydroxyboryl derivative of phenylalanine called boronophenylalanine. The major challenge in the development of boron delivery agents has been the requirement for selective tumor targeting to achieve boron concentrations (∼20 μg/g tumor) sufficient to deliver therapeutic doses of radiation to the tumor with minimal normal tissue toxicity. Over the past 20 years, other classes of boron-containing compounds have been designed and synthesized that include boron-containing amino acids, biochemical precursors of nucleic acids, DNA-binding molecules, and porphyrin derivatives. High molecular weight delivery agents include monoclonal antibodies and their fragments, which can recognize a tumor-associated epitope, such as epidermal growth factor, and liposomes. However, it is unlikely that any single agent will target all or even most of the tumor cells, and most likely, combinations of agents will be required and their delivery will have to be optimized. Clinical Trials: Current or recently completed clinical trials have been carried out in Japan, Europe, and the United States. The vast majority of patients have had high-grade gliomas. Treatment has consisted first of “debulking” surgery to remove as much of the tumor as possible, followed by BNCT at varying times after surgery. Sodium borocaptate and boronophenylalanine administered i.v. have been used as the boron delivery agents. The best survival data from these studies are at least comparable with those obtained by current standard therapy for glioblastoma multiforme, and the safety of the procedure has been established. Conclusions: Critical issues that must be addressed include the need for more selective and effective boron delivery agents, the development of methods to provide semiquantitative estimates of tumor boron content before treatment, improvements in clinical implementation of BNCT, and a need for randomized clinical trials with an unequivocal demonstration of therapeutic efficacy. If these issues are adequately addressed, then BNCT could move forward as a treatment modality.read more
Citations
More filters
Journal ArticleDOI
Review of laser-driven ion sources and their applications.
TL;DR: The historical background including the early laser-matter interaction studies on energetic ion acceleration relevant to inertial confinement fusion is reviewed and several implemented and proposed mechanisms of proton and/or ion acceleration driven by ultra-short high-intensity lasers are described.
Journal ArticleDOI
Nanomaterials: Applications in Cancer Imaging and Therapy
TL;DR: A brief description of cancer pathology and the characteristics that are important for tumor‐targeted NM design are provided, followed by an overview of the different types of NMs explored to date, covering synthetic aspects and approaches explored.
Journal ArticleDOI
Targeting nanoparticles to cancer.
TL;DR: There is still a room for optimisation in the area of the nanoparticle kinetics such as improving their plasma circulation and tumour bioavailability and understanding the effect of targeting ligands on their efficiency to treat cancer.
Journal ArticleDOI
Carbaboranes as Pharmacophores: Properties, Synthesis, and Application Strategies
Journal ArticleDOI
Boron in drug discovery: carboranes as unique pharmacophores in biologically active compounds.
TL;DR: Boron in Drug Discovery: Carboranes as Unique Pharmacophores in Biologically Active Compounds Fatiah Issa, Michael Kassiou, and Louis M. Rendina.
References
More filters
Journal ArticleDOI
A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival
Michel Lacroix,Dima Abi-Said,Daryl R. Fourney,Ziya L. Gokaslan,Weiming Shi,Franco DeMonte,Frederick F. Lang,Ian E. McCutcheon,Samuel J. Hassenbusch,Eric C. Holland,Kenneth R. Hess,Christopher Michael,Daniel J. Miller,Raymond Sawaya +13 more
TL;DR: Gross-total tumor resection is associated with longer survival in patients with GBM, especially when other predictive variables are favorable.
Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials
Walter J. Curran,Charles B. Scott,John Horton,James S. Nelson,Alan S. Weinstein,A. J. Fischbach,C. H. Chang,Marvin Rotman,Sucha O. Asbell,Robert E. Krisch,D. F. Nelson +10 more
TL;DR: This study of malignant glioma patients used a non-parametric statistical technique to examine the associations of both pretreatment patient and tumor characteristics and treatment-related variables with survival duration and permits examination of the interaction between prognostic variables not possible with other forms of multivariate analysis.
Journal ArticleDOI
Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma Trials
Walter J. Curran,Charles B. Scott,John Horton,James S. Nelson,Alan S. Weinstein,A. Jennifer Fischbach,Chu H. Chang,Marvin Rotman,Sucha O. Asbell,Robert E. Krisch,D. F. Nelson +10 more
TL;DR: In this paper, the authors used a nonparametric statistical technique to examine the associations of both pretreatment patient and tumor characteristics and treatment-related variables with survival duration for malignant glioma patients.
Journal ArticleDOI
The Chemistry of Neutron Capture Therapy.
Albert H. Soloway,Werner Tjarks,Beverly A. Barnum,Feng-Guang Rong,Rolf F. Barth,I. M. Codogni,J. G. Wilson +6 more
Journal ArticleDOI
Promising Survival for Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Concomitant Radiation Plus Temozolomide Followed by Adjuvant Temozolomide
Roger Stupp,Pierre Yves Dietrich,Sandrine Ostermann Kraljevic,Alessia Pica,Ivan Maillard,Phillipe Maeder,Reto Meuli,Robert C. Janzer,Gianpaolo Pizzolato,Raymond Miralbell,F. Porchet,Luca Regli,Nicolas de Tribolet,René O. Mirimanoff,Serge Leyvraz +14 more
TL;DR: This regimen of concomitant chemoradiotherapy followed by adjuvant chemotherapy may prolong the survival of patients with glioblastoma.